Ocular bacterial infections cause a significant number of cases of blindness worldwide. Efforts to prevent damage to delicate ocular tissues during infection rely on swift and proper use of therapeutics to rapidly kill organisms and arrest potentially damaging inflammation. Currently-used antibiotics can kill organisms, but the effectiveness of anti-inflammatory drugs is controversial. These drug classes do not target tissue-damaging toxins synthesized by bacteria at the site of infection. Pore-forming toxins (PFTs) are important, and often essential, to ocular virulence of the following Gram-positive ocular pathogens: Staphylococcus aureus, Streptococcus pneumoniae, Bacillus cereus, and Enterococcus faecalis. When PFTs are absent, ocular virulence is significantly decreased. Novel PFT-targeting therapeutics which neutralize toxins across species would provide coverage for the most common Gram-positive pathogens causing ocular surface (keratitis) and intraocular (endophthalmitis) infections. Toxin neutralization as an adjunct with antibiotics and anti-inflammatory agents would provide a significant improvement over current therapies that are ineffective against tissue-damaging toxins. Nanosponges have recently been developed which target Gram-positive PFTs. In vitro, nanosponges neutralize Gram-positive PFTs. In in vivo experimental models of sepsis and tissue infection, nanosponges neutralize toxins at the site of infection and reduce virulence. We hypothesize that nanosponges can effectively reduce the toxic activity of bacterial PFTs in the ocular environment, leading to use as a novel anti-toxi therapeutic with antibiotics for the treatment of intraocular and ocular surface infections. Preliminary data demonstrates the feasibility of testing our hypothesis. We show that nanosponges 1) neutralize PFTs of Gram-positive ocular pathogens, 2) do so in the presence of tears, vitreous, and antibiotics, 3) protect against toxic ocular cell death, and 4) are not toxic in/on mouse eyes. A critical barrier to clinical improvements in ocular bacterial infections is th absence of toxin- targeting. We will test nanosponges for PFT-neutralizing activity and efficacy with antibiotics against ocular pathogens causing keratitis (Aim 1) and endophthalmitis (Aim 2), and will also investigate their biodistribution following ocular application (Aim 3). If nanosponge are effective, the next step is to test nanosponges with more potent antibiotics and better anti-inflammatory agents. Testing of nanosponges in the treatment of ocular bacterial infections is high risk, but is novel, high-impact, translationally relevant, and will positively influence the ocular infectious disease field by identifying a novel anti-toxin therapy which may protect delicate tissues of the eye during infection. The proposed studies are a logical outgrowth of our ocular infection research program, and we are well positioned to contribute valuable information which will provide physicians with the best possible therapeutic options to preserve vision during ocular infections.

Public Health Relevance

Currently-used therapeutics for ocular bacterial infections include antibiotics (which kill organisms) and anti- inflammatory drugs (whose value for these infections is controversial); however, these therapeutics do not address tissue-damaging toxins synthesized by bacteria at the site of infection. Pore-forming toxins (PFTs) are important, and often essential, to the ocular virulence of Gram-positive ocular pathogens, and nanosponges have recently been developed which neutralize Gram-positive PFTs. This proposal will test nanosponges for PFT-neutralizing activity and efficacy with antibiotics against ocular pathogens in models of keratitis and endophthalmitis in experiments which are novel, high-impact, translationally relevant, and will potentially identify a new type of anti-toxin therapy that may protect delicate ocular tissues and improve visual outcomes during ocular infections.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
7R01EY025947-02
Application #
9143134
Study Section
Special Emphasis Panel (ZRG1-BDCN-R (05)M)
Program Officer
Mckie, George Ann
Project Start
2015-09-30
Project End
2018-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
2
Fiscal Year
2016
Total Cost
$359,315
Indirect Cost
$84,000
Name
University of Oklahoma Health Sciences Center
Department
Type
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Chen, Yijie; Chen, Mengchun; Zhang, Yue et al. (2018) Broad-Spectrum Neutralization of Pore-Forming Toxins with Human Erythrocyte Membrane-Coated Nanosponges. Adv Healthc Mater 7:e1701366
Coburn, Phillip S; Miller, Frederick C; LaGrow, Austin L et al. (2018) TLR4 modulates inflammatory gene targets in the retina during Bacillus cereus endophthalmitis. BMC Ophthalmol 18:96
Gao, Weiwei; Chen, Yijie; Zhang, Yue et al. (2018) Nanoparticle-based local antimicrobial drug delivery. Adv Drug Deliv Rev 127:46-57
Angsantikul, Pavimol; Fang, Ronnie H; Zhang, Liangfang (2018) Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles. Bioconjug Chem 29:604-612
LaGrow, Austin L; Coburn, Phillip S; Miller, Frederick C et al. (2017) A Novel Biomimetic Nanosponge Protects the Retina from the Enterococcus faecalis Cytolysin. mSphere 2:
Escajadillo, Tamara; Olson, Joshua; Luk, Brian T et al. (2017) A Red Blood Cell Membrane-Camouflaged Nanoparticle Counteracts Streptolysin O-Mediated Virulence Phenotypes of Invasive Group A Streptococcus. Front Pharmacol 8:477
Callegan, Michelle C; Parkunan, Salai Madhumathi; Randall, C Blake et al. (2017) The role of pili in Bacillus cereus intraocular infection. Exp Eye Res 159:69-76
Lapek Jr, John D; Fang, Ronnie H; Wei, Xiaoli et al. (2017) Biomimetic Virulomics for Capture and Identification of Cell-Type Specific Effector Proteins. ACS Nano 11:11831-11838
Wei, Xiaoli; Gao, Jie; Wang, Fei et al. (2017) In Situ Capture of Bacterial Toxins for Antivirulence Vaccination. Adv Mater 29:
Dehaini, Diana; Wei, Xiaoli; Fang, Ronnie H et al. (2017) Erythrocyte-Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization. Adv Mater 29:

Showing the most recent 10 out of 13 publications